Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why Idera Pharmaceuticals (IDRA) Could Be Positioned for a Surge
Zacks Equity Research
ZacksDecember 2, 2016
Idera Pharmaceuticals, Inc. IDRA is a drug discovery and development company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on IDRA’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Idera Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for IDRA
In the past 30 days, 3 estimates have gone higher for Idera Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates with estimates narrowing from a loss of 11 cents a share 30 days ago, to a loss of 8 cents today, a move of 27.3%.
Current Year Estimates for IDRA
Meanwhile, Idera Pharmaceuticals’s current year figures are also looking quite promising, with 4 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 45 cents per share 30 days ago to a loss of 38 cents per share today, an increase of 15.6%.
IDERA PHARMACT Price and Consensus
Chart omitted
IDERA PHARMACT Price and Consensus | IDERA PHARMACT Quote
Bottom Line
The stock has also started to move higher lately, adding 7.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
______________________________________________
http://finance.yahoo.com/news/why-idera-pharmaceuticals-idra-could-160304050.html
IDRA
Yeh, surprised me. Haven't followed long enough to know their pipeline. So they did very well dragging the discard from their basement. Sure helped the balance sheet as you suggested. Had seen comments suggesting the latest financing was not enough -- now should be. Assume they were aware of the potential deal when they established the level of financing.
IDRA
Commentary from Investopedia:
__________________________________________
Idera Signs Licensing Pact for Nixed GI Drug (IDRA) By Shobhit Seth | November 29, 2016 — 9:27 AM EST
Nasdaq-listed Idera Pharmaceuticals Inc. (IDRA) sold the licensing rights of its previously scrapped autoimmune drug IMO-9200 to privately-held Vivelix Pharmaceuticals Ltd.
Hamilton, Bermuda-based Vivelix was founded earlier this year by former Salix Pharmaceuticals employees.
The specialty drug company develops drugs for gastrointestinal and liver diseases. (See also: Valeant May Sell Salix Unit for $10 Billion.)
$15M Upfront and $140M Potential Milestones
As a part of the deal, Idera will receive an upfront payment of $15 million from Vivelix, with future potential milestone payments totaling up to $140 million and increasing royalties ranging from the mid-single digits to low double-digit percentage of global sales.
The deal also has provisions for the development of backup compounds in case IMO-9200 fails. Vivelix can ask Idera to develop back-up compounds to IMO-9200, which would be at Vivelix’s expense. Idera will be able to receive payments totaling up to $52.5 million for drug development, regulatory sales and milestones.
IMO-9200’s History
The IMO-9200 drug works by restraining a protein class called toll-like receptors, whose activation can lead to autoimmune disorders like rheumatoid arthritis and multiple sclerosis. (See also: Regeneron Rheumatoid Arthritis Drug Outperforms Humira.)
In the most recent quarterly filings, Idera said it will “not to proceed with the development of IMO-9200 because the large autoimmune disease indications for which IMO-9200 had been developed did not fit within the strategic focus of our company.”
Idera ended the third quarter with only $22.15 million cash and cash equivalents, so the upfront payment of $15 million from Vivelix will bolster its cash position.
Idera also raised money in a secondary public offering in October, but the development was not perceived positively by the market. The company's stock price tanked from $2.61 per share to $1.81 between October 5 and October 11, 2016. (For more, see Idera Announces $50M Public Offering.)
Following the Vivelix deal announcement, Idera's stock price hit $2.02 per share on November 28, and eventually closed at $1.80.
Read more: Idera Signs Licensing Pact for Nixed GI Drug (IDRA) | Investopedia http://www.investopedia.com/news/idera-signs-licensing-pact-nixed-gi-drug-idra/#ixzz4RPfsbcgs
Follow us: Investopedia on Facebook
______________________________________________
IDRA
See that Wedbush reiterated yesterday:
11/28/2016 Wedbush Reiterated Rating Outperform $6.00 View Rating Details
10/7/2016 S&P Equity Research Boost Price Target $1.86 -> $2.10 View Rating Details
5/10/2016 Cowen and Company Reiterated Rating Buy View Rating Details
3/12/2016 Piper Jaffray Cos. Reiterated Rating Buy View Rating Details
6/15/2015 JPMorgan Chase & Co. Initiated Coverage Overweight $6.00
https://www.marketbeat.com/stocks/NASDAQ/IDRA/
IDRA
What you say makes sense. I just keep beating myself up for not selling pre-market at a decent price and buying back whole. Was trying to but misjudged. Thought the drop at about 9:15 was the typical MM shakeout and would go back up. With the market being down everything compounded. It takes great news to overcome the market trend and as you say the deal might not be the strongest. Can't find out much about the partner because they are private -- would feel more confident if the partnership was with a larger, more stable company.
Lets hope the BB's are correct.
Two BB sources:
http://whalewisdom.com/filer/baker-bros-advisors-llc
http://www.j3sg.com/Reports/Stock-Insider/Generate-Institution-Portfolio.php?institutionid=4698&DV=yes
IDRA
Watch the bid and ask on the Level II. There is always a .05 difference (Bid @ $3.40 and Ask @ $3.45). This difference is there throughout the day. MMs can trade between such as $3.43. The .05 tick difference is part of SEC trial which seemed to start at the beginning of November,
____________________________________________
"SEC Finalizes ‘Tick Size’ Pilot for Smaller-Company Stock
http://www.wsj.com/articles/sec-finalizes-tick-size-pilot-for-smaller-company-stock-1430949237
WASHINGTON—The stock prices of more than 1,000 small U.S. companies will trade in increments of five cents under a long-awaited plan the Securities and Exchange Commission finalized late Wednesday.
"The SEC voted to finalize the highly-anticipated test program that will run for two years beginning next May. It’s designed to determine whether trading the stocks of smaller companies in wider “tick sizes,” or the difference between what traders bid and offer for the shares, will boost interest in the stocks.
The move is a shift from more than a decade of requiring trading in pennies. Wider increments, advocates of the plan say, will allow traders to reap higher rewards, giving them more of an incentive to trade the stocks and lessen volatility. Critics say its goals are aspirational and will accomplish little other than to make trading in certain shares more expensive for investors.
The program will apply to firms with $3 billion or less in market capitalization, down from the $5 billion initially expected."
__________________________________________
Been watching several small biotech stocks trading under this trial and it seems they are more volatile, but not sure whether AEZS might be less volatile.
Saw a $heff tweet yesterday:
"Sheff ?@SheffStation 16h16 hours ago
I really dislike the 5 cent increment biotech stocks. They really screw over shareholders in a stock."
AEZS
.
Lengthy bullish SA article regarding PANW:
http://seekingalpha.com/article/4026621-palo-alto-networks-time-dip-toes-back?app=1&auth_param=udil:1c3ofjg:a452fd5bf50d83f8697874daff6999db&uprof=46
PANW
Thought it would at least stay above $2.00. Following the biopharm sector which is down or maybe the uncertainty and newness of the partner??
http://vivelix.com/
IDRA
Not sure if it has been noted before, but AEZS is on the Nasdaq trial of minimum spread of .05 between bid and ask.
(I have no shares)
AEZS
Got to assume Baker was aware when this purchase was made:
BAKER JULIAN Director 10/03/2016 Acquisition (Non Open Market) indirect 24,897 2.5600 7,174,124
Read more: http://www.nasdaq.com/symbol/idra/insider-trades#ixzz4RJAIcdja
IDRA
The PR:
Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200
By GlobeNewswire, November 28, 2016, 07:00:00 AM EDT
Idera receives $15 million upfront, with potential IMO-9200-related milestone payments totaling up to $140 million plus royalties
CAMBRIDGE, Mass., EXTON, Pa. and HAMILTON, Bermuda, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), and Vivelix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive license and collaboration agreement granting Vivelix worldwide rights to develop and market IMO-9200, an antagonist of TLR 7,8 and 9, for non-malignant gastrointestinal disorders. As part of the agreement, Idera has agreed to create and characterize potential back-up compounds for Vivelix.
"We are excited to acquire an asset as innovative and potentially transformational as IMO-9200," stated Bill Forbes, President & CEO at Vivelix Pharmaceuticals Ltd. "All of us at Vivelix look forward to developing this potentially life-changing therapy for patients suffering from gastrointestinal diseases."
"The team at Vivelix has a tremendous track record in successful development and marketing of products in the gastrointestinal disease category," stated Vincent Milano, Idera's Chief Executive Officer. "We are pleased to be able to enter into this agreement with a team that we are confident can guide IMO-9200 through the next phases of development and ultimately into the hands of physicians and patients suffering from these severe, debilitating conditions."
Under the terms of the agreement, Idera will receive an upfront fee of $15 million. In addition, Idera will be eligible for future IMO-9200 related development, regulatory and sales milestone payments totaling up to $140 million, and escalating royalties ranging from the mid single-digits to low double-digits of global net sales. Additionally, under the terms of the agreement and if requested by and at Vivelix's expense, Idera is responsible for developing potential back-up compounds to IMO-9200. As it relates to back-up compounds Idera will be eligible for related development, regulatory sales and milestone payments totaling up to $52.5 million and escalating royalties ranging from the mid single-digits to low double-digits of global net sales.
About IMO-9200
IMO-9200 is an orally delivered, synthetic oligonucleotide-based antagonist of toll-like receptor (TLR) 7,8 and 9. IMO-9200 had demonstrated activity in several pre-clinical studies of disorders characterized by acute and chronic inflammation in the gastrointestinal tract. Additionally, IMO-9200 was demonstrated to be safe and tolerable in a Phase 1 clinical trial in healthy subjects.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera's proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
About Vivelix Pharmaceuticals Ltd.
Vivelix Pharmaceuticals, Ltd. is a newly formed, privately held specialty pharmaceutical company focused on licensing, developing and commercializing gastroenterology and hepatology drugs. Staffed by an experienced management team, Vivelix was founded in 2016 by seven former employees of Salix Pharmaceuticals, Inc., a specialty gastroenterology/hepatology company. The Vivelix team brings nearly 150 collective years of drug development and commercialization experience, with more than 10 drug approvals and accompanying product launches in gastroenterology and hepatology. To learn more about Vivelix, please visit www.vivelix.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the Company's strategy, future operations, collaborations, intellectual property, cash resources, financial position, future revenues, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Idera cannot guarantee that it will actually achieve the intentions or expectations of the transaction disclosed herein and you should not place undue reliance on the Company's forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated or implied by its forward-looking statements. Factors that may cause such a difference include: whether products based on Idera's IMO-9200 technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the products receive approval, they will be successfully distributed and marketed by Vivelix; and such other important factors as are set forth under the caption "Risk Factors" in the Company's Annual Report and on Form 10-Q for the period ended September 30, 2016. Although Idera may elect to do so at some point in the future, the Company does not assume any obligation to update any forward-looking statements and it disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor and Media Contacts
For Idera:
Robert Doody
Vice President, Investor Relations and Corporate Communications
Office: 617-679-5515
Mobile: 484-639-7235
rdoody@iderapharma.com
For Vivelix:
Daniel P. Lundberg
Chief Marketing Officer
Office: 984-204-7535
ir@vivelix.comVivelix Pharmaceuticals Ltd., Clarendon House, 2 Church Street, Hamilton, HM11, Bermuda
Source: Idera Pharmaceuticals, Inc.
Read more: http://www.nasdaq.com/press-release/idera-pharmaceuticals-and-vivelix-pharmaceuticals-ltd-enter-into-exclusive-license-agreement-for-20161128-00198#ixzz4RJ8Hz8Bd
_____________________________________
IDRA
Updated November Fact Sheet now in iBox. Also here:
http://ir.aezsinc.com/sites/aezsinc.investorhq.businesswire.com/files/doc_library/file/Fact_sheet_MASTER_November2016.pdf
AEZS
Out @ $139.38 after hours on the 23rd after the stream of Form 4's from the CEO and others. Never know the market reaction, but not a good indicator.
PANW
Hope you are right. Bought @ $139.66 thinking there might be a big drop below $140 -- although it went even lower.
Seems the drop out of proportion to the mixed quarterly. New to Palo Alto but obviously a good sector to be in especially with Trump prioritizing cyber-security.
PANW
I'm in -- a lot of information to review. Didn't realize how comprehensive the site is. Thanks, now to profit.
Thanks for the heads up. I think I'll give it a try unless I find it requires a long term commitment.
Ended up selling at $14.15 to keep profits:
FWIW:
SunTrust unsure of potential for higher TubeMogul bid After a regulatory filing detailed other interested bidders for TubeMogul (TUBE), SunTrust analyst Matthew Thornton says he does not know whether a higher bid will surface. The stock is trading above the $14 price offered by Adobe (ADBE) on the potential that Party A and/or Party C, as they are referred to in today's filing, could return with a higher bid, Thornton tells investors in a research note. Party A seemed to indicate $14 was too high while Party C couldn't make a proposal under the prior time constraint, the analyst adds. He has a Hold rating on TubeMogul with a $14 price target.
Read more at:
http://thefly.com/landingPageNews.php?id=2466090
TUBE
TubeMogul rises after disclosing interest from parties other than Adobe Shares of TubeMogul (TUBE) are up 1.6% to $14.23 in afternoon trading after the company gave details about its negotiations with Adobe (ADBE) in a filing earlier, including the revelation that other potential buyers also expressed interest in the company. In the filing, TubeMogul stated in part: "On the morning of November 4, a representative of Morgan Stanley and a senior member of Adobe's corporate development team discussed the current status over the phone. The representative of Morgan Stanley informed Adobe that the TubeMogul Board was planning to pursue an offer from another strategic bidder unless Adobe made an offer that day. The agreement with the other bidder was in a form they were potentially willing to sign and subsequently announce as early as the following Monday, November 7, according to the Morgan Stanley representative. However, the representative of Morgan Stanley conveyed that the TubeMogul Board would be prepared to enter into exclusive negotiations with Adobe if Adobe made a written offer for $14.00 per share in cash and committed to negotiate and sign a definitive agreement by Wednesday, November 9...On November 7, the parties met at Weil's offices in Redwood Shores, California, where they conducted due diligence throughout the day. Representatives of PwC joined those meetings on behalf of Adobe to participate in financial and tax due diligence. As those meetings were in progress, as required by the exclusivity agreement, a representative of Morgan Stanley informed the Adobe team that two other potential bidders were continuing to reach out regarding TubeMogul and confirmed that Morgan Stanley and TubeMogul did not respond to those communications."
Read more at:
http://thefly.com/landingPageNews.php?id=2466065
____________________________________________
TUBE
DealPointData - M&A @DPD_Mergers Posted: 11/18/2016, 11:25:22 AM
Adobe Systems $ADBE has launched their $14.00 per sh in cash tender offer for TubeMogul $TUBE, which is scheduled to expire on December 16
Read more: http://www.nasdaq.com/symbol/tube/stream#ixzz4QNWyfw8F
TUBE
Thanks, sometimes like to confirm the chart with BarChart (which if you haven't used lately has recently updated their site so it is much better imo):
https://www.barchart.com/stocks/quotes/IDRA/cheat-sheet
They seem to be a bit more bullish, but as you say needs volume which actually seems pretty good today.
IDRA
I agree. Was a bit surprised that it retained it's pps prior to the presentation as the sector was down. Management had noted prior to Stifel that it would only be a corporate overview but traders often don't read such stuff.
Two takeaways that I heard were cash good through 2017 and updates at conferences in early 2017, I believe Feb was mentioned. Correct me if I'm wrong.
I believe that being a penny stock, MMs do a bit more manipulation than with higher priced stocks. You can see these strange trades watching the Level II especially pre and post market. Also, Google Finance has it at an extremely high "Beta 2.56".
Personally looking for a good exit, in fact had a limit sell in all day yesterday but never reached my sell level.
IDRA
Webcast link:
http://wsw.com/webcast/stifel5/idra/index.aspx
IDRA
Fantastic news for you. Congrats.
You know I didn't know that Ophir had closed his position, but don't subscribe to his service. However, follow his tweets throughout the day < https://twitter.com/OphirGottlieb >. He is good. Adam Singer credits Ophir as having alerted him to TUBE. You subscribe?
I'm still in TUBE and see that it is creeping back to $14.00. Good luck.
TUBE
Had sold on Friday @ $24.10 because wasn't going to available on the 14th for earnings. Looking to re-enter -- anyone else?
ZOES
Still holding with the thought there may be another, higher offer, but beginning to doubt. Hope it is safe. Some think Adobe got it too cheap.
Picked up the company name from https://twitter.com/AdamSinger who works for Google in the marketing analytics area and felt good about his bullish view because he could see the potential of its technology's marketing value.
TUBE
Wedbush outperform:
11/14/2016 Wedbush Reiterated Rating Outperform $6.00
https://www.marketbeat.com/stocks/NASDAQ/IDRA/
IDRA
With the 2 board positions I'm sure the Baker Bros were aware of the data and bought at $2.00 so can't be that bad. Of course they take a long, long point of view.
IDRA
They did -- sell the news. Good news but more confirmatory than "to the moon". Hopefully strong enough to keep us up until LABU/XBI have real strong days. I guess patience.
You still in?
IDRA
From the just released PR:
“We hypothesized that the intratumoral injection of IMO-2125 into a single tumor lesion would stimulate dendritic cells to produce interferon and the downstream immune cascade in the tumor microenvironment, resulting in the recruitment and activation of tumor-killing T-cells in both the injected and non-injected tumors,” said Joanna Horobin, M.B., Ch.B., Idera’s Chief Medical Officer. “When combined with a systemic checkpoint inhibitor, this change in the tumor microenvironment was expected to affect tumor responses in both injected and distant tumors. Today Dr. Haymaker presented analyses of serial biopsies from the tumors of patients with anti-PD-1 refractory melanoma in our ongoing phase 1 dose escalation trial of intratumoral IMO-2125 which clearly demonstrated these beneficial changes in the tumor microenvironment, essentially turning “cold” tumors “hot” in responding patients. We are thrilled to see what we believe to be, the clear translation of our hypothesis in patients. Moreover, in three patients the investigator has reported substantial tumor shrinkage with 2 partial and one complete response.”
IDRA
Interesting that despite the presentation at 3:15 today, the pps are moving very closely in line with the LABU. Use Google finance and enter LABU to see comparative movement with IDRA:
https://www.google.com/finance?q=idra&ei=y9olWPCAOcXDjAHmv66ADQ
IDRA
Sure looking better so far today headed to the 3:15 presentation. Up 3% while LABU down -3%.
IDRA
A couple of others have launched the typical "investigations":
TUBE News: TUBEMOGUL, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 11:51 AM
TUBE News: TubeMogul (TUBE) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sa...
TUBE
You probably saw this:
______________________________________
Bristol-Myers hands over $100M in cash for a new fibrosis drug, beefing up NASH focus
by john carroll
November 10, 2016 06:59 AM EST
Updated: 08:20 AM
It’s not all checkpoints all the time at Bristol-Myers Squibb. The big biotech has been ramping up an ambitious effort in fibrosis and NASH and this morning it’s taking the wraps off another deal in the field, paying $100 million to Japan’s Nitto Denko for an early-stage drug candidate that now becomes part of their portfolio.
The key drug in this package deal is ND-L02-s0201, a siRNA that is designed to inhibit heat shock protein 47. By hitting HSP47, their investigators believe that they can cut the production of collagen that plays a role in fibrosis and NASH, while helping correct at least some of the damage that has already been done to patients.
The drug is undergoing a 5-week Phase Ib study now to give them a better idea of how the drug works for fibrosis caused by NASH, an epidemic fatty liver disease, and hepatitis C. And Bristol-Myers gets the rights to Nitto Denko’s portfolio in the field, bagging exclusive rights for fibrosis in a variety of diseases.
The deal includes milestones, which weren’t discussed in their statement.
Nitto Denko is a century-old diversified materials manufacturer based in Osaka with a newfound interest in diversifying into biotech. Early this year the company established a biotech subsidiary called Nitto BioPharma, with facilities in San Diego and plans to continue to pursue R&D in IPF and other diseases.
Bristol-Myers execs have been putting a brave face on their recent debacle in frontline non-small cell lung cancer for their PD-1 pioneer Opdivo. The late-stage failure left a bad scar, but the company points to its R&D work in fibrosis/NASH and heart failure as examples of a more diversified pipeline.
Back in August, 2015, the ambitious R&D group struck a $1.25 billion deal — $150 million up front — to gain an option to acquire Promedior if its mid-stage fibrosis program comes through.
Bristol-Myers has its sights set on PRM-151, a recombinant form of human pentraxin-2 protein in development for idiopathic pulmonary fibrosis and myelofibrosis. The company scored another provisional buyout agreement for Denmark’s Galecto in 2014, agreeing to pay up to $444 million for the company. That deal centered on TD139, an inhibitor of galectin-3, which binds to carbohydrate structures, playing a role in IPF that can be derailed by this new drug. TD139 joined BMS-986020, a lysophosphatidic acid 1 (LPA1) receptor antagonist also in studies for fibrosis. Bristol-Myers also struck research deals with the California Institute for Biomedical Research (Calibr) and The Medical University of South Carolina.
_______________________________________________
BMY
Bristol-Myers nabs global rights to liver fibrosis candidates, including NASH, from Nitto Denko
Nov. 10, 2016 8:15 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
Bristol-Myers Squibb (NYSE:BMY) inks a worldwide licensing agreement with Osaka, Japan-based Nitto Denko (OTCPK:NDEKF)(OTCPK:NDEKY) for the development and commercialization of Nitto's siRNA molecules targeting heat shock protein 47 (HSP47) formulations containing vitamin A. The deal includes Nitto's lead product candidate, Phase 1b-stage ND-L02-s0201, for the treatment of advanced liver fibrosis and grants BMY the option for secure exclusive licenses for HSP47 sirRNAs in vitamin A formulations for the treatment of lung fibrosis and other organ fibrosis.
Under the terms of the agreement, Nitto will receive an upfront payment of $100M, milestones, sales-based royalties and option exercise payments for lung and other organ fibrosis. BMY will be responsible for the development, manufacture and commercialization of HSP47 sirRNAs in vitamin A formulations for all liver diseases.
Fibrotic diseases are characterized by inflammation and subsequent formation of excess collagen (scarring) in the organ or tissue. Nitto's ND-L02-s0201 is a targeted siRNA designed to inhibit HSP47, a collagen-specific chaperone that regulates collagen synthesis and secretion, and prevent further collagen formation while resolving existing fibrosis. It has Fast Track status in the U.S. for the treatment of liver fibrosis and cirrhosis secondary to NASH and liver fibrosis and cirrhosis secondary to HCV infection.
__________________________________________
http://seekingalpha.com/news/3223332-bristol-myers-nabs-global-rights-liver-fibrosis-candidates-including-nash-nitto-denko?app=1&uprof=46#email_link
BMY